IBDEI13J ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18306,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,18306,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,18306,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,18307,0)
 ;;=L54.^^94^905^145
 ;;^UTILITY(U,$J,358.3,18307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18307,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,18307,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,18307,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,18308,0)
 ;;=L56.0^^94^905^139
 ;;^UTILITY(U,$J,358.3,18308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18308,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,18308,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,18308,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,18309,0)
 ;;=L56.1^^94^905^138
 ;;^UTILITY(U,$J,358.3,18309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18309,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,18309,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,18309,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,18310,0)
 ;;=L56.2^^94^905^236
 ;;^UTILITY(U,$J,358.3,18310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18310,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,18310,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,18310,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,18311,0)
 ;;=L56.3^^94^905^268
 ;;^UTILITY(U,$J,358.3,18311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18311,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,18311,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,18311,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,18312,0)
 ;;=L57.0^^94^905^12
 ;;^UTILITY(U,$J,358.3,18312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18312,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,18312,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,18312,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,18313,0)
 ;;=L60.0^^94^905^161
 ;;^UTILITY(U,$J,358.3,18313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18313,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,18313,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,18313,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,18314,0)
 ;;=L60.1^^94^905^234
 ;;^UTILITY(U,$J,358.3,18314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18314,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,18314,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,18314,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,18315,0)
 ;;=L60.2^^94^905^233
 ;;^UTILITY(U,$J,358.3,18315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18315,1,3,0)
 ;;=3^Onychogryphosis
 ;;^UTILITY(U,$J,358.3,18315,1,4,0)
 ;;=4^L60.2
 ;;^UTILITY(U,$J,358.3,18315,2)
 ;;=^5009235
 ;;^UTILITY(U,$J,358.3,18316,0)
 ;;=L60.3^^94^905^170
 ;;^UTILITY(U,$J,358.3,18316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18316,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,18316,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,18316,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,18317,0)
 ;;=L60.4^^94^905^88
 ;;^UTILITY(U,$J,358.3,18317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18317,1,3,0)
 ;;=3^Beau's Lines
 ;;^UTILITY(U,$J,358.3,18317,1,4,0)
 ;;=4^L60.4
 ;;^UTILITY(U,$J,358.3,18317,2)
 ;;=^5009237
 ;;^UTILITY(U,$J,358.3,18318,0)
 ;;=L60.5^^94^905^290
 ;;^UTILITY(U,$J,358.3,18318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18318,1,3,0)
 ;;=3^Yellow Nail Syndrome
 ;;^UTILITY(U,$J,358.3,18318,1,4,0)
 ;;=4^L60.5
 ;;^UTILITY(U,$J,358.3,18318,2)
 ;;=^5009238
 ;;^UTILITY(U,$J,358.3,18319,0)
 ;;=L60.8^^94^905^168
 ;;^UTILITY(U,$J,358.3,18319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18319,1,3,0)
 ;;=3^Nail Disorders NEC
 ;;^UTILITY(U,$J,358.3,18319,1,4,0)
 ;;=4^L60.8
 ;;^UTILITY(U,$J,358.3,18319,2)
 ;;=^5009239
 ;;^UTILITY(U,$J,358.3,18320,0)
 ;;=L62.^^94^905^169
